SCHEMBL6959378

SCHEMBL6959378

O=c1oc(-c2cccc(C(F)(F)F)c2)cc(O)c1SCCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.41
PTPN6 P29350 2/20 0.41
PTPRC P08575 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN9 P43378 1/20 0.41
DUSP3 P51452 1/20 0.41
PTPN11 Q06124 1/20 0.41
PTPN22 Q9Y2R2 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 2/20 0.40
CNR2 P34972 1/20 0.40
POLB P06746 1/20 0.39
SLC9A1 P19634 1/20 0.39
HTR2B P41595 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6965413 0.90 DAO (0.44) PTPN1PTPN6PTPRCPTPN2PTPN9
SCHEMBL7369560 0.87 SMN1; SMN2 (0.38) CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E
SCHEMBL6959678 0.86 SMN1; SMN2 (0.42) CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E
SCHEMBL6960622 0.86 SMN1; SMN2 (0.49) CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E
SCHEMBL6966516 0.83 GABRP (0.44) PTPN1CYP1A2CYP1A1CYP1B1ALDH1A1
SCHEMBL6959687 0.81 POLB (0.38) PTPN1PTPN6PTPRCPTPN2PTPN9
SCHEMBL6954657 0.81 SMN1; SMN2 (0.44) CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E
SCHEMBL6960719 0.81 AR (0.39) PTPN1PTPN6PTPN2CYP1A2CYP1A1
SCHEMBL7369564 0.81 SMN1; SMN2 (0.36) CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E
SCHEMBL6956148 0.80 PTGES (0.45) CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed